The impact of tranexamic acid on perioperative outcomes in urological surgeries A systematic review and meta-analysis.

ABSTRACT:

Introduction

Tranexamic acid (TXA) is an antifibrinolytic agent widely used in surgery to decrease bleeding and reduce the need for blood product transfusion. The role of TXA in urology is not well-summarized. We conducted a systematic review of studies reporting outcomes of TXA use in urological surgery.

Methods

A comprehensive search was conducted from the following databases: PubMed, Embase, Cochrane Library, and Web of Science. Two reviewers performed title and abstract screening, full-text review, and data collection. Primary outcomes included estimated blood loss (EBL), decrease in hemoglobin, decrease in hematocrit, and blood transfusion rates. Secondary outcomes included TXA administration characteristics, length of stay, operative time, and postoperative thromboembo

SUBMITTER: Kim J 

PROVIDER: S-EPMC10263287 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature